Pesticidal compositions and processes related thereto
US-9215870-B2 · Dec 22, 2015 · US
Chemical modulators of immune checkpoints and therapeutic use
US10562864B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10562864-B2 |
| Application number | US-201816191243-A |
| Country | US |
| Kind code | B2 |
| Filing date | Nov 14, 2018 |
| Priority date | Dec 30, 2015 |
| Publication date | Feb 18, 2020 |
| Grant date | Feb 18, 2020 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
Compounds and pharmaceutical compositions that down-regulate immune checkpoints such as PD-1, PD-L1 and CTLA-4 are provided. Also provided are methods of treating a disease by down-regulating immune checkpoints such as PD-1, PD-L1 and CTLA-4. The methods are useful for treating cancer and viral infection in a subject.
First claim
Opening claim text (preview).
What is claimed is: 1. A compound selected from the group consisting of: 4-fluoro-2-(5-nitro-1H-benzo[d]imidazol-2-yl)phenol; 6-chloro-2-(trifluoromethyl)-N-(4-(trifluoromethyl)phenyl)-1H-benzo[d]imidazole-4-carboxamide; and 4-chloro-2-(5-(4-nitrophenyl)-4H-1,2,4-triazol-3-yl)phenol, or a pharmaceutically acceptable salt thereof. 2. A pharmaceutical composition comprising at least one pharmaceutically acceptable carrier and an effective amount of a compound of claim 1 or a pharmaceutically acceptable salt thereof. 3. The compound of claim 1 , wherein the compound is 6-chloro-2-(trifluoromethyl)-N-(4-(trifluoromethyl)phenyl)-1H-benzo[d]imidazole-4-carboxamide, or a pharmaceutically acceptable salt thereof. 4. The pharmaceutical composition of claim 2 , wherein the compound is 6-chloro-2-(trifluoromethyl)-N-(4-(trifluoromethyl)phenyl)-1H-benzo[d]imidazole-4-carboxamide, or a pharmaceutically acceptable salt thereof.
Assignees
Inventors
Classifications
- C07D249/08Primary
1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles · CPC title
with aryl radicals directly attached in position 2 · CPC title
containing heavy metals, e.g. hemin, hematin, melarsoprol · CPC title
condensed with carbocyclic rings, e.g. benzimidazoles · CPC title
ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US10562864B2 cover?
- Compounds and pharmaceutical compositions that down-regulate immune checkpoints such as PD-1, PD-L1 and CTLA-4 are provided. Also provided are methods of treating a disease by down-regulating immune checkpoints such as PD-1, PD-L1 and CTLA-4. The methods are useful for treating cancer and viral infection in a subject.
- Who is the assignee on this patent?
- Univ Duke
- What technology area does this patent fall under?
- Primary CPC classification C07D249/08. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Feb 18 2020 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).